Cas No.: | 854001-07-3 |
Chemical Name: | 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-, hydrochloride (1:1) |
Synonyms: | BMS-354825 hydrochloride;BMS354825 hydrochloride;BMS 354825 hydrochloride |
SMILES: | O=C(NC1C(Cl)=CC=CC=1C)C1SC(NC2C=C(N3CCN(CCO)CC3)N=C(C)N=2)=NC=1.[H]Cl |
Formula: | C22H27Cl2N7O2S |
M.Wt: | 524.4665 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | A potent, orally bioavailable, dual Src/Abl kinase inhibitor with IC50 of 0.5, 0.4, 0.5 and <1 nM for Src, Lck, Yes and Bcr-Abl, respectively; exhibits two-log increased potency relative to imatinib and retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants; prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-positive bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.Blood CancerApproved |